Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência.
Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.
Blocking the EGFR signaling pathway using the breast cancer treatment lapatinib significantly reduces the amount of adrenocorticotropic hormone (ACTH) produced by pituitary tumor cells and their proliferation in mice, ... Read more
Cushing’s disease patients whose pituitary tumors carry a USP8 mutation are more likely to achieve remission after surgery than those without such mutations, a retrospective Italian study found. The ... Read more
Cushing’s syndrome patients deemed in biological remission are rarely functionally cured, continuing to report low quality of life scores, chronic depression, and the need for specific working arrangements in ... Read more
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to fluasterone (ST-002) for the treatment of nonalcoholic fatty liver disease, nonalcoholic steatosis, and high blood sugar in Cushing’s syndrome patients, SteroTherapeutics announced. ... Read more
Strongbridge Biopharma recently received a second patent from the U.S. Patent and Trademark Office covering the use of Recorlev (levoketoconazole) for the treatment of Cushing’s syndrome. The patent (No. 9,918,984) is titled “Methods ... Read more
Thanks to a $10 million endowment from the Li Weibo Charitable Foundation in China, the University of Massachusetts Medical School will soon be able to launch a new institute dedicated to ... Read more
Crinetics Pharmaceuticals has received two grants from the National Institutes of Health’s (NIH) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to develop nonpeptide, oral somatostatin agonists ... Read more
Five European countries have agreed to Verona Pharma’s plan to begin enrolling patients in a Phase 2b clinical trial of RPL554 as a maintenance treatment for chronic obstructive pulmonary disease, or COPD. The ... Read more
Pin It on Pinterest